- Home
- » Tags
- » Atezolizumab
Top View
- Immunotherapy Combinations and Sequences in Urothelial Cancer: Facts and Hopes Alejo Rodriguez-Vida1, Jose Luis Perez-Gracia2, and Joaquim Bellmunt1,3
- Radiochemistry, Production Processes, Labeling Methods, and Immunopet Imaging Pharmaceuticals of Iodine-124
- (INN) for Biological and Biotechnological Substances
- Combination Treatment with Paclitaxel, Carboplatin, and Cetuximab (PCE) As First-Line Treatment in Patients with Recurrent And/Or Metastatic Nasopharyngeal Carcinoma
- Kite a Gileau Company
- Enfortumab Vedotin-Ievx) NDA/BLA Multi-Disciplinary Review and Evaluation
- Solid Tumor – Dr. Gralow TNBC
- Atezolizumab (TECENTRIQ) National Drug Monograph August 2016 VA Pharmacy Benefits Management Services, Medical Advisory Panel, and VISN Pharmacist Executives
- Atezolizumab
- Q2 2019 Clinical Trials Appendices
- Targeting HER2 in Breast Cancer: New Drugs and Paradigms on the Horizon Paolo Tarantino1,2 , Stefania Morganti1,2 , Giuseppe Curigliano1,2*
- 1. Metastatic HER2 Positive HR POSITIVE BREAST
- Important Prescribing Information
- TECENTRIQ Prescribing Information
- Optimizing Sequential Systemic Therapies for Advanced Hepatocellular Carcinoma: a Decision Analysis
- Atezolizumab for Metastatic Non–Small Cell Lung Cancer Chana Weinstock, Sean Khozin, Daniel Suzman, Lijun Zhang, Shenghui Tang, Sakar Wahby, Kirsten B
- Premium Value
- Descargar Este Archivo
- CLINICAL TRIAL ANNOUNCEMENT Phase I /II Trial to Evaluate Isatuximab in Patients with Advanced Malignancies
- Atezolizumab: Drug Information
- R&D Pipeline – New Molecular Entities
- Second-Line Treatment for Advanced NSCLC Without Actionable Mutations: Is Immunotherapy the ‘Panacea’ for All Patients? Alessandro Morabito
- Immune Checkpoint Inhibitors in Triple-Negative Breast Cancer Full Abbreviations, Accreditation, and Disclosure Information Available at Peerview.Com/EKR40
- Highlights in Metastatic Breast Cancer from the European Society for Medical Oncology Virtual Congress 2020
- 761137Orig1s000
- Safety and Efficacy of Atezolizumab
- Oncology Therapy for the Generalist
- (DARZALEX®) and Atezolizumab in Multiple Myeloma and Solid Tumor
- Atezolizumab and Granzyme B As Immunotoxin Against PD-L1 Antigen; an Insilico Study
- June 30, 2021 Total Approvals 269 This Report Will Be Updated January and July of Every Year
- Tecentriq, INN-Atezolizumab
- Antibody–Drug Conjugates for the Treatment of Breast Cancer
- WO 2017/176965 Al 12 October 2017 (12.10.2017) P O P C T
- Antibody–Drug Conjugates: Future Directions in Clinical And
- Immunotherapy with CD19-Specific Chimeric Antigen
- International Nonproprietary Names for Pharmaceutical Substances (INN)
- GI Phase I Clinical Trial Portfolio Slot Study Number Disease Status Study Title Basic Eligibility Availability HCC Studies
- Evolving Therapies for Urothelial Carcinoma —Novel Paradigms and Future Directions
- The Navigating and De-Risking Role of 89Zr-Immuno-PET in the Development of Biopharmaceuticals
- Tecentriq, INN-Atezolizumab
- Current Treatments of Metastatic Colorectal Cancer with Immune Checkpoint Inhibitors—2020 Update
- (INN) for Biological and Biotechnological Substances
- FDA Approves First New ALS Drug in Over 20 Years
- Precision Cancer Therapy
- Greenberg Bladder Cancer Institute
- 802 Ramucirumab Plus Atezolizumab in Patients with Stage IV Non-Small
- Modeling Pharmacokinetics and Pharmacodynamics of Therapeutic Antibodies: Progress, Challenges, and Future Directions
- Roche to Present New Data from Its Broad Oncology Portfolio at The
- MORPHEUS: a Phase Ib/II Study Platform Evaluating The
- Crosstalk Between HER2 and PD-1/PD-L1 in Breast Cancer: from Clinical Applications to Mathematical Models
- Atezolizumab Lampalizumab Taselisib Nmes Venetoclax Lebrikizumab Olesoxime Etrolizumab
- Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma Thomas Powles, M.D., Jonathan E
- Statistical Analysis Plan
- Severe Treatment-Refractory T-Cell-Mediated Immune Skin
- The Breast Cancer Drug Market
- 761041Orig1s000
- Targeted Molecular Therapeutics for Bladder Cancer—A New Option Beyond the Mixed Fortunes of Immune Checkpoint Inhibitors?
- GU CANCERS 2019… There Is Always Something New to Talk About…
- Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab
- AML in Adult Patients -Presentation
- TECENTRIQ (Atezolizumab) Injection for Intravenous Use Is a Sterile, Preservative-Free, Colorless to Slightly Yellow Solution in Single-Dose Vials
- HER2-Overexpressing/Amplified Breast Cancer As a Testing Ground for Antibody-Drug Conjugate Drug Development in Solid Tumors
- Rituximab (Riabni™, Rituxan®, Ruxience®, & Truxima®)
- INN-Nimet 1 20.8.2019 a Abacavir Abacavirum Abakaviiri
- Emerging Immunotherapy for Acute Myeloid Leukemia